{"id":"W4205825534","doi":"10.1038/s41375-021-01485-x","title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"AstraZeneca","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Internal medicine; Bruton's tyrosine kinase; Oncology; Clinical endpoint; Leukemia; Clinical trial; Chemotherapy; Tyrosine kinase; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003454093,0.0004221469,0.001521543,0.0002635319,0.0005569739,0.001340415,0.0005175634,0.004162434,0.002142034],"category_scores_gemma":[0.006745127,0.0002864103,0.001798444,0.0005490507,0.0004692817,0.00084812,0.00025395,0.003163834,0.0007519442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001709801,"about_ca_system_score_gemma":0.0007977841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001809944,"about_ca_topic_score_gemma":0.002411537,"domain_scores_codex":[0.9983725,0.0007230399,0.0001831408,0.0002418598,0.0002671577,0.0002122962],"domain_scores_gemma":[0.9945307,0.002947218,0.0008734229,0.0002930937,0.0005318738,0.0008236975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4043885,0.01065897,0.2560751,0.0006539388,0.005722981,0.01295433,0.0007847228,0.003560563,0.01098227,0.001048804,0.07084247,0.2223274],"study_design_scores_gemma":[0.1332829,0.1519424,0.5981748,0.0003878596,0.00979769,0.01655634,0.0005189318,0.009719057,0.006933355,0.004598135,0.0677738,0.0003146346],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9305052,0.01124194,0.0006632783,0.0384922,0.001542143,0.0003144018,0.00485803,0.00006976349,0.01231301],"genre_scores_gemma":[0.9548348,0.001635737,0.0005570792,0.03217192,0.001965035,0.0001938767,0.003029093,0.00002247084,0.005589914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004162434,"threshold_uncertainty_score":0.01826721,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04697134715739797,"score_gpt":0.3070144821862215,"score_spread":0.2600431350288235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}